Pancreatic cancer data collection method and pancreatic cancer detection kit

The method of using lectins and antibodies to measure extracellular vesicles in body fluids addresses the low predictive value of existing pancreatic cancer tests, enabling early detection and monitoring.

JP7591205B2Active Publication Date: 2024-11-28JVC KENWOOD CORP +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2020147108
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-09-01
Publication Date
2024-11-28
Estimated Expiration
2040-09-01

AI Technical Summary

Technical Problem

Existing liquid biopsies for pancreatic cancer detection have low positive predictive value, making it difficult to detect early-stage pancreatic cancer effectively.

Method used

A method involving the use of extracellular vesicles in body fluids, which are brought into contact with specific lectins to measure their binding, and comparing the amount to a control to detect pancreatic cancer, utilizing lectins such as DSA, STL, LEL, ACA, UDA, ABA, MAH, and TJA-1, and antibodies to pan-extracellular vesicle membrane proteins like CD9 and CD63.

Benefits of technology

Enables early detection and monitoring of pancreatic cancer through a minimally invasive liquid biopsy, improving diagnostic accuracy and therapeutic monitoring.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591205000002
    Figure 0007591205000002
  • Figure 0007591205000003
    Figure 0007591205000003
  • Figure 0007591205000004
    Figure 0007591205000004
Patent Text Reader

Abstract

To provide a pancreatic cancer detection method capable of early detection of pancreatic cancer and monitoring of therapeutic effect, and a pancreatic cancer detection kit.SOLUTION: The pancreatic cancer detection method includes: a step (a) of bringing extracellular vesicles in the body fluid sample derived from a subject into contact with one or more lectins; a step (b) of measuring the amount of the extracellular vesicles bound to one or more lectins after the step (a); and a step (c) of assessing the presence of pancreatic cancer in the subject based on the amount of the extracellular vesicles measured in step (b). The pancreatic cancer detection kit includes a solid-phase carrier on which one or more lectins are immobilized, and antibodies that specifically bind to pancellular extracellular vesicle membrane proteins or antigen-binding fragments thereof.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to pancreatic cancer Data collection The present invention relates to a method and a kit for detecting pancreatic cancer. [Background technology]

[0002] The number of deaths from pancreatic cancer is increasing year by year. In 2018, the number of cancer deaths in Japan was 33,475, ranking fourth among all causes of cancer deaths. In recent years, not only have surgical techniques been improved, but multidisciplinary treatment strategies such as preoperative treatment (chemotherapy, radiation therapy, etc.) and postoperative adjuvant therapy have been developed. As a result, although long-term outcomes have improved compared to the past, there are still many challenges when looking at malignant neoplasms as a whole. The reason for this is that pancreatic cancer is often diagnosed as advanced cancer despite advances in imaging diagnosis, and the resection rate at the time of diagnosis is about 30%, and even if radical resection is achieved through highly difficult surgery, it has a high rate of recurrence, and is resistant to existing chemotherapy and radiation therapy.

[0003] One of the reasons why early diagnosis of pancreatic cancer is difficult is the unique nature of the pancreas, which makes it difficult to directly collect samples from it compared to other organs with cancer. Although diagnostic accuracy has improved with improvements in the resolution of imaging tests, there is no established method that can effectively screen for pancreatic cancer. In addition, although endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become widespread for collecting tissue and diagnostic capabilities have improved, there are issues with the possibility of seeding due to puncture and the invasiveness of the method, and there is a demand for simpler and less invasive methods for testing pancreatic cancer.

[0004] For these reasons, liquid biopsy, a testing method that uses bodily fluid (such as blood) samples to examine cancer-derived molecules to diagnose cancer or evaluate the effectiveness of treatment, is attracting attention for pancreatic cancer. Existing tumor markers for pancreatic cancer detection used in liquid biopsy include carbohydrate antigens such as CA19-9, Span-1, CA50, CA242, Dupan-2, TAG-72, and urinary fucose, and antigens other than carbohydrate antigens such as CEA, POA, and TPS (Non-Patent Document 1). These tumor markers have good sensitivity but not high specificity, and have the problem of a high false positive rate. Furthermore, the positive predictive value for pancreatic cancer is generally low except for advanced cancer, and even for pancreatic cancers less than 2 cm in size, the positive predictive value of CA19-9 is only 52%, which is only half. Therefore, tumor markers have a problem in detecting early pancreatic cancer. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Japan Pancreas Society, Pancreatic Cancer Treatment Guidelines Revision Committee, Pancreatic Cancer Treatment Guidelines 2009 Edition, Diagnostic Methods, "CQ1 Diagnostic Methods, CQ1-3 If pancreatic cancer is suspected, what should be the first test?", [online], [Retrieved July 10, 2020], Internet<URL:http: / / www.suizou.org / PCMG2009 / cq1 / cq1-3.html> Summary of the Invention [Problem to be solved by the invention]

[0006] A simple and minimally invasive test method is required for the early diagnosis of pancreatic cancer. However, the positive predictive value of conventional liquid biopsy using tumor markers is generally low, making it difficult to detect early-stage pancreatic cancer.

[0007] Therefore, the present invention enables early detection of pancreatic cancer and monitoring of treatment effects by liquid biopsy. Collect data to , pancreatic cancer Data collection The present invention aims to provide a method and a kit for detecting pancreatic cancer. [Means for solving the problem]

[0008] The present invention includes the following aspects. [1] A step (a) of contacting extracellular vesicles in a body fluid sample derived from a subject with one or more lectins, and a step (b) of measuring the amount of the extracellular vesicles bound to the one or more lectins after the step (a). And, Including pancreatic cancer Data collection method. [2 ]Pancreas When the amount of extracellular vesicles that bind to the one or more lectins measured in step (b) is greater than the amount of extracellular vesicles that bind to the one or more lectins measured in a body fluid sample of a subject known not to have pancreatic cancer, the subject is diagnosed with pancreatic cancer. Likely thing Show , [1] Pancreatic cancer Data collection method. [3] The pancreatic cancer according to [1] or [2], wherein the one or more lectins include at least one selected from the group consisting of DSA, STL, LEL, ACA, UDA, ABA, MAH, and TJA-1. Data collection method. [4] A method for detecting pancreatic cancer described in any one of [1] to [3], wherein the step (b) is carried out using an antibody or an antigen-binding fragment thereof that specifically binds to a pan-extracellular vesicle membrane protein. [5] The pancreatic cancer according to [4], wherein the pan-extracellular vesicle membrane protein is selected from the group consisting of CD9, CD63, and CD81. Data collection method. [6] A pancreatic cancer detection kit comprising a solid phase carrier having one or more lectins immobilized thereon, and an antibody or an antigen-binding fragment thereof that specifically binds to a pan-extracellular vesicle membrane protein. [7] The pancreatic cancer detection kit described in [6], wherein the one or more lectins include at least one selected from the group consisting of DSA, STL, LEL, ACA, UDA, ABA, MAH, and TJA-1. [8] The pancreatic cancer detection kit described in [6] or [7], wherein the pan-extracellular vesicle membrane protein is selected from the group consisting of CD9, CD63, and CD81. [9] A pancreatic cancer detection kit described in any one of [6] to [8], wherein an antibody or an antigen-binding fragment thereof that specifically binds to the pan-extracellular vesicle membrane protein is immobilized on a solid-phase carrier particle.

[10] The pancreatic cancer detection kit according to any one of [6] to [9], further comprising an extracellular vesicle capture unit for use in an extracellular vesicle counter used to count extracellular vesicles, and the solid phase carrier is provided in the extracellular vesicle capture unit. Effect of the Invention

[0009] According to the present invention, liquid biopsy enables early detection of pancreatic cancer and monitoring of the effectiveness of treatment. Collect data to , pancreatic cancer Data collection Methods and kits for detecting pancreatic cancer are provided. [Brief description of the drawings]

[0010] [Figure 1A] 1 shows an example of a solid phase carrier to which a lectin is immobilized, which is used in a pancreatic cancer detection method according to one embodiment of the present invention. [Figure 1B] FIG. 2 is a diagram illustrating an example of step (a) of the pancreatic cancer detection method according to one embodiment of the present invention. [Figure 1C] FIG. 2 is a diagram illustrating an example of step (b) of the pancreatic cancer detection method according to one embodiment of the present invention. [Figure 2A] FIG. 1 is a schematic diagram showing an example of an extracellular vesicle capture unit set in an extracellular vesicle counter. [Figure 2B] FIG. 2B is a schematic cross-sectional view of the extracellular vesicle capture unit of FIG. 2A along the AA section line. [Figure 2C] FIG. 2B is a schematic cross-sectional view illustrating that the cartridge 52 of the extracellular vesicle capturing unit in FIG. 2A is removable. [Figure 3A] FIG. 7B is a schematic cross-sectional view of the extracellular vesicle capture unit of FIG. 7A along the line BB. [Figure 3B] FIG. 7A is an enlarged cross-sectional view illustrating the dimensions and shapes of the recesses and protrusions of the extracellular vesicle capture unit. [Figure 4] The figures show the results of measuring the number of exosomes bearing glycans that bind to ABA or ACA (hereinafter also referred to as "ABA / ACA-specific exosomes") using culture supernatants of various cancer cell lines (pancreatic cancer cell lines: BxPC33, Capan-1; breast cancer cell line: MCF7; colon cancer cell line: HCT116; lung cancer cell line: A549). [Diagram 5] The ratio of ABA / ACA-specific exosome count to total exosome count in the culture supernatant used in Figure 1 is shown. [Figure 6] The figures show the results of measuring the number of ABA / ACA-specific exosomes using serum from healthy individuals (NC) and serum from pancreatic cancer patients before surgery (PC / Preoperative) and after surgery (PC / Postoperative). [Figure 7] The figures show the results of measuring the number of ABA / ACA-specific exosomes using sera from pancreatic cancer patients (PC), esophageal cancer patients (Esophageal Cancer), and colorectal cancer patients (Colorectal Cancer). [Figure 8] The figures show the results of measuring the number of ABA / ACA-specific exosomes using serum from healthy individuals (NC) and serum from patients with stage I, II, and III pancreatic cancer. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] Hereinafter, an embodiment of the present invention will be described in detail with reference to the drawings as needed. In the drawings, the same or corresponding parts are denoted by the same or corresponding reference numerals, and duplicate explanations are omitted. The dimensional ratios in each drawing are exaggerated for the purpose of explanation, and do not necessarily correspond to the actual dimensional ratios.

[0012] (Pancreatic cancer detection method) In one embodiment, the present invention provides a method for detecting pancreatic cancer. The method for detecting pancreatic cancer in this embodiment includes the steps of: (a) contacting extracellular vesicles in a body fluid sample derived from a subject with one or more lectins; (b) measuring the amount of the extracellular vesicles bound to the one or more lectins after the step (a); and (c) evaluating the presence of pancreatic cancer in the subject based on the amount of the extracellular vesicles measured in the step (b).

[0013] The pancreatic cancer detection method of this embodiment will be outlined with reference to FIGS. 1A to 1C. The solid phase carrier 1 in FIG. 1A is an example of a solid phase carrier used to bring extracellular vesicles into contact with lectin 10. The solid phase carrier 1 has a recess 2 and a protrusion 3, and lectin 10 is immobilized in the recess 2. When a body fluid sample derived from a subject is added to the solid phase carrier 1, the extracellular vesicles (E1, E2) in the body fluid sample can be brought into contact with the lectin 10 (step (a): FIG. 1B).

[0014] Extracellular vesicle E1 has sugar chains 21 and 22, and sugar chain 21 has an affinity for lectin 10 and therefore binds to lectin 10. On the other hand, extracellular vesicle E2 has sugar chains 22 and 23, but these sugar chains do not have an affinity for lectin 10 and therefore do not bind to lectin 10.

[0015] Next, the amount of extracellular vesicles E1 bound to the lectin 10 is measured (step (b): FIG. 1C). For example, the amount of extracellular vesicles E1 can be measured by binding an antibody 41 that binds to a pan-extracellular vesicle membrane protein to the extracellular vesicles E1 and detecting the signal of the label bound to the antibody 41. In the example of FIG. 1C, the antibody 41 is fixed to a solid-phase carrier particle 40, and the signal of the solid-phase carrier particle 40 is detected.

[0016] Next, the presence of pancreatic cancer in the subject is evaluated based on the amount of extracellular vesicles E1 measured. For example, when the amount of extracellular vesicles E1 measured in step (b) is greater than the amount measured in the body fluid sample of a healthy subject, the subject is evaluated to have pancreatic cancer.

[0017] In the pancreatic cancer detection method of the present embodiment, as described above, pancreatic cancer is detected using the amount of extracellular vesicles that bind to lectin as an index. Extracellular vesicles are vesicles released by cells. The size of extracellular vesicles is about 30 nm to 1 μm in diameter. Examples of extracellular vesicles include exosomes, apoptotic bodies, and microvesicles. In the pancreatic cancer detection method of this embodiment, the extracellular vesicles used as indicators are preferably exosomes. Exosomes are membrane vesicles surrounded by a lipid bilayer membrane with a diameter of about 50 to 150 nm, and are intraluminal membrane vesicles that bud inwardly into the endosomal lumen and are secreted into body fluids from various cells including cancer cells.

[0018] Extracellular vesicles are secreted products of cells, and express various proteins derived from the cell of secretion on their surface. Glycosylation, which is one of the post-translational modifications of proteins, is present on all cell membranes and secretory proteins, and its structure is thought to change due to cell differentiation and canceration. The membrane proteins of extracellular vesicles are also glycosylated, and the glycosylation structure differs depending on the cell of secretion. The pancreatic cancer detection method of this embodiment is based on the finding that the amount of extracellular vesicles that have binding properties to a specific lectin in a body fluid sample is increased (or decreased) in individuals with pancreatic cancer compared to individuals without pancreatic cancer.

[0019] [Process (a)] In step (a), extracellular vesicles in a body fluid sample derived from a subject are contacted with one or more lectins. Step (a) is an in vitro process.

[0020] "Body fluid sample derived from a subject" refers to a body fluid sample collected from a subject, and a sample obtained by subjecting a body fluid sample collected from a subject to some treatment. The body fluid sample derived from a subject is not particularly limited as long as it contains extracellular vesicles. The method of treating the body fluid sample collected from the subject is not particularly limited, and examples thereof include a treatment to remove cellular components (e.g., centrifugation treatment), a treatment to dilute with a buffer solution (PBS, PBS-T, saline, Tris buffer solution, etc.), etc.

[0021] The body fluid sample is not particularly limited as long as it contains extracellular vesicles. Since extracellular vesicles are present stably in most body fluids, most body fluids can be used. Examples of body fluid samples include, but are not limited to, blood, serum, plasma, saliva, urine, tears, sweat, milk, nasal secretions, semen, pleural fluid, gastrointestinal secretions, cerebrospinal fluid, interstitial fluid, and lymphatic fluid. Extracellular vesicles are relatively stable even in body fluids that have been collected from a subject and then stored for a long period of time under refrigeration or freezing. Therefore, body fluid samples that have been stored for a long period of time after collection can also be used. As the body fluid sample derived from a subject, serum or plasma is preferred, and serum is more preferred.

[0022] "Subject" refers to an individual animal that is the subject of pancreatic cancer detection. The subject is not particularly limited as long as it is an animal in which pancreatic cancer can occur, and examples of the subject include humans and non-human mammals. Examples of non-human mammals include primates (monkeys, chimpanzees, gorillas, etc.), rodents (mice, hamsters, rats, etc.), rabbits, dogs, cats, cows, goats, sheep, horses, etc. Preferably, the subject is a human.

[0023] Lectins are proteins that have binding properties to sugar chains. The lectins to be contacted with extracellular vesicles in a body fluid sample may be one or more, or two or more. The type of lectin is not particularly limited, but preferably includes at least one selected from the group consisting of DSA, STL, LEL, ACA, UDA, ABA, MAH, and TJA-1. As shown in the Examples described below, it has been confirmed that extracellular vesicles that bind to these lectins are significantly increased in pancreatic cancer patients compared to healthy subjects. Among the above, the lectin preferably includes at least one selected from the group consisting of ACA and ABA.

[0024] The lectin may be a mutant of the above-mentioned lectins, so long as it retains the ability to bind to glycans. The term "mutant lectin" refers to a protein having an amino acid sequence in which one or more amino acids in the amino acid sequence of a lectin have been mutated, and which has the same glycan-binding ability as the original lectin. The amino acid mutation is at least one type selected from the group consisting of substitution, addition, deletion, and insertion. Examples of lectin mutants include (1) a protein consisting of an amino acid sequence in which one or more amino acids have been mutated in the amino acid sequence of an original lectin and having the glycan-binding ability of the original lectin; and (2) A protein consisting of an amino acid sequence having 80% or more sequence identity with the amino acid sequence of the original lectin and having the glycan-binding ability of the original lectin. In the above (1), "multiple" can be, for example, 2 to 20, 2 to 15, 2 to 10, 2 to 5, 2 to 4, or 2 or 3. In the above (2), the sequence identity is preferably 85% or more, more preferably 90% or more, even more preferably 95% or more, and particularly preferably 96% or more, 97% or more, 98% or more, or 99% or more. The sequence identity between amino acid sequences is determined by aligning two amino acid sequences with gaps at the insertion and deletion sites so that the corresponding amino acids are most identical, and calculating the ratio of the identical amino acids to the entire amino acid sequence excluding the gaps in the alignment obtained. The sequence identity between amino acid sequences can be determined using various homology search software known in the technical field. For example, the value of the sequence identity of amino acid sequences can be obtained by calculation based on the alignment obtained by the known homology search software BLASTP. Preferred variants include those in which some of the amino acids constituting the original lectin are conservatively substituted. "Conservative substitution" refers to substitution with an amino acid having similar biochemical properties. Examples of conservative substitutions include substitutions between alanine, valine, leucine, and isoleucine, which have aliphatic side chains; substitutions between serine and threonine, which have hydroxyl side chains; substitutions between aspartic acid and glutamic acid, which have acidic side chains; substitutions between asparagine and glutamine, which have amide side chains; substitutions between lysine and arginine, which have basic side chains; and substitutions between phenylalanine and tryptophan, which have aromatic side chains.

[0025] The method of contacting extracellular vesicles in a body fluid sample with one or more lectins is not particularly limited. For example, a solid phase carrier 1 on which a lectin 10 is immobilized as shown in FIG. 1A may be used. The solid phase carrier 1 in FIG. 1A has a recess 2 and a protrusion 3, and the lectin 10 is immobilized in the recess 2. In this case, as shown in FIG. 1B, by supplying a body fluid sample containing extracellular vesicles to the solid phase carrier 1, the extracellular vesicles (E1, E2 in FIG. 1B) can be brought into contact with the lectin 10. When the extracellular vesicles are brought into contact with the lectin 10, the extracellular vesicle E1 has a sugar chain 21 that has a binding ability to the lectin 10, so that the extracellular vesicle E1 binds to the lectin 10 via the sugar chain 21 and is captured in the recess 2. On the other hand, the extracellular vesicle E2 does not bind to the lectin 10 because it does not have a sugar chain that has a binding ability to the lectin 10. Therefore, only the extracellular vesicle E1 that has a binding ability to the lectin 10 can be captured on the solid phase carrier 1.

[0026] The material of the solid phase carrier 1 is not particularly limited, and examples thereof include resins such as polystyrene, polyolefin (polyethylene, polypropylene, etc.), cycloolefin polymer, polycarbonate, and glass. The solid phase carrier 1 may be a well plate whose surface has been treated so that lectin can bind thereto, and the recess 2 may be a well of the well plate. Alternatively, the solid phase carrier 1 may be a substrate having a surface treated with the recess 2 and the protrusion 3 provided thereon. The lectin 10 can be immobilized on the solid phase carrier 1 by a known method. For example, the surface on which the lectin is immobilized may be surface-treated so that the protein is physically adsorbed by surface hydrophobic interaction, or may be surface-treated so that it has amino groups or carboxyl groups. Alternatively, the lectin 10 may be immobilized on the recess 2 by utilizing avidin-biotin binding.

[0027] When two or more types of lectins are used as the lectins to be contacted with the extracellular vesicles, it is preferable to contact each type of lectin with the extracellular vesicles. For example, in the example of FIG. 1A, one type of lectin is immobilized on one solid phase carrier 1, and a solid phase carrier 1 is prepared for each type of lectin. Then, a body fluid sample is supplied to each of the multiple solid phase carriers 1, and the lectin 10 is contacted with the extracellular vesicles in the body fluid sample.

[0028] After contacting the extracellular vesicles with the lectin 10, the solid phase carrier 1 may be washed appropriately with a washing solution. By washing the solid phase carrier 1, extracellular vesicles that are not bound to the lectin 10 can be removed. The washing solution is not particularly limited, and a washing solution used for washing in ELISA or the like can be used. Examples of the washing solution include a buffer solution or a buffer solution to which a surfactant such as Tween 20 has been added. Examples of the washing solution include, but are not limited to, PBS, PBS-T, Tris buffer solution, HEPES buffer solution, pure water, and the like.

[0029] The contact between the extracellular vesicles in the body fluid sample and the lectin is not limited to the method using the solid phase carrier 1, and any method known in the art can be used. For example, the contact between the extracellular vesicles in the body fluid sample and the lectin may be performed using magnetic beads to which the lectin is immobilized. In this case, the extracellular vesicles bound to the lectin can be collected by collecting the magnetic beads.

[0030] In addition, contact between the extracellular vesicles in the body fluid sample and the lectin may be performed in the liquid phase by adding the lectin to the body fluid sample. In this case, the extracellular vesicles bound to the lectin can be collected using a solid phase carrier or the like to which a sugar chain or an antibody that specifically binds to the lectin is immobilized. Here, "specifically bind" means that the substance has high binding affinity to the target substance and has almost no binding affinity to other substances.

[0031] Alternatively, the extracellular vesicles may be first captured on a solid support via an antibody or the like that specifically binds to the pan-extracellular vesicle membrane protein, and then a solution containing the lectin may be supplied onto the solid support to bring the extracellular vesicles into contact with the lectin. Here, the term "pan-extracellular vesicle membrane protein" refers to a membrane protein that is ubiquitously present in extracellular vesicles. The pan-extracellular vesicle membrane protein may be a membrane protein that is ubiquitously present in all extracellular vesicles, such as exosomes, apoptotic bodies, and microvesicles, or may be a membrane protein that is normally expressed in any of exosomes, apoptotic bodies, and microvesicles. For example, the pan-extracellular vesicle membrane protein may be a membrane protein that is ubiquitously present in exosomes (hereinafter also referred to as "pan-exosomal membrane protein"). "Ubiquitously present in extracellular vesicles" refers to a membrane protein that is present in a wide variety of extracellular vesicles. "Ubiquitously present in exosomes" refers to a membrane protein that is present in a wide variety of exosomes. Examples of pan-exosome membrane proteins include CD9, CD63, and CD81.

[0032] When the lectin is not fixed to the solid phase carrier 1, the lectin may be labeled with a labeling molecule. As the labeling molecule, a fluorescent molecule, etc., described below, can be preferably used. By using the labeled lectin, the extracellular vesicles bound to the lectin can be measured in step (b) described below by detecting the labeling molecule used for the labeling. Alternatively, the lectin may be fixed to a solid phase carrier particle 40 described below. In this case, the extracellular vesicles bound to the lectin can be measured in step (b) described below by detecting the signal of the solid phase carrier particle 40 with an extracellular vesicle measuring device, etc.

[0033] [Step (b)] In step (b), after step (a), the amount of the extracellular vesicles bound to the one or more lectins is measured. Step (b) is a step performed in vitro.

[0034] The amount of extracellular vesicles bound to the lectin may be measured by the number of extracellular vesicles, the amount of proteins specifically expressed in the extracellular vesicles, or the volume of the extracellular vesicles.

[0035] The amount of extracellular vesicles bound to lectin (hereinafter also referred to as "lectin-specific extracellular vesicles") can be measured, for example, by using a pan-extracellular vesicle protein expressed by the extracellular vesicles. Such a method is not particularly limited, and a method normally used for detecting proteins can be used. For example, in FIG. 1C, extracellular vesicles E1 bound to lectin 10 are measured using solid-phase carrier particles 40 to which an antibody 41 that binds to a pan-extracellular vesicle membrane protein is immobilized. The antibody 41 is an antibody that specifically binds to the pan-extracellular vesicle membrane protein 31, and when a solution containing the antibody 41 is supplied onto the solid-phase carrier 1, it binds to the extracellular vesicles E1 captured in the recess 2. Therefore, the extracellular vesicles E1 can be measured by measuring the solid-phase carrier particles 40.

[0036] The material of the solid-phase carrier particles 40 is not particularly limited, and examples thereof include resins such as polystyrene and glycidyl methacrylate; magnetic beads, etc. The solid-phase carrier particles 40 can be measured, for example, by irradiating the solid-phase carrier 1 with a laser beam and analyzing the reflected light from the solid-phase carrier 1.

[0037] When the measurement target is an exosome, a pan-exosome membrane protein can be selected as the pan-exosome membrane protein 31. Examples of the pan-exosome membrane protein include CD9, CD63, and CD81. The antibody 41 can be produced by a known antibody production method (such as the hybridoma method or the phage display method) using a pan-extracellular vesicle membrane protein as an antigen. The antibody 41 may be a polyclonal antibody or a monoclonal antibody. The animal from which the antibody 41 is derived is not particularly limited, and any animal commonly used for antibody production can be used, such as a goat antibody, a mouse antibody, a rat antibody, a rabbit antibody, a monkey antibody, or a human antibody. The antibody 41 does not need to be an intact antibody, and may be an antigen-binding fragment. The term "antigen-binding fragment" refers to a polypeptide that contains a part of an antibody and maintains the antigen-binding ability of the original antibody. Examples of antigen-binding fragments include scFv, Fab, F(ab')2, and Fv. The antibody 41 may also be a modified antibody such as a chimeric antibody.

[0038] The antibody 41 can be immobilized on the solid-phase carrier particle 40 by a known method. For example, the same method as the method for immobilizing the lectin 10 on the solid-phase carrier 1 can be used.

[0039] When using solid-phase carrier particles 40 with fixed antibodies 41, a commercially available extracellular vesicle measuring instrument (e.g., an exosome measuring instrument) can be used to detect the solid-phase carrier particles 40. The "extracellular vesicle measuring instrument" is an instrument that can count extracellular vesicles by detecting the signal of a signal substance directly or indirectly bound to the extracellular vesicles. The solid-phase carrier particles 40 function as the signal substance. As a commercially available extracellular vesicle measuring instrument, for example, ExoCounter (registered trademark) (JVC Kenwood) can be used. When using an extracellular vesicle measuring instrument, the solid-phase carrier 1 and the solid-phase carrier particles 40 can be those described in detail in the "Pancreatic Cancer Detection Kit" described later.

[0040] Measurement of lectin-specific extracellular vesicles (extracellular vesicles E1) may be performed using a labeling molecule instead of the solid phase carrier particles 40. For example, the antibody 41 is labeled with a labeling molecule, and the extracellular vesicles E1 can be measured by measuring the signal of the labeling molecule. As the labeling molecule, a labeling molecule generally used in ELISA or the like can be used without any particular limitation. Examples of labeling molecules include labeling substances such as enzyme labels, such as peroxidase (e.g., horseradish peroxidase) and alkaline phosphatase; fluorescent labels, such as carboxyfluorescein (FAM), 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein (JOE), fluorescein isothiocyanate (FITC), tetrachlorofluorescein (TET), 5'-hexachloro-fluorescein-CE phosphoramidite (HEX), Cy3, Cy5, Alexa568, and Alexa647; radioisotope labels, such as iodine-125; electrochemiluminescent labels, such as ruthenium complexes; biotin; and metal nanoparticles. The detection of the signal of the labeling molecule can be performed by a known method according to the labeling molecule used. For example, a labeled antibody that specifically binds to a pan-extracellular vesicle membrane protein is bound to a lectin-specific extracellular vesicle, and the amount of the pan-extracellular vesicle membrane protein expressed by the lectin-specific extracellular vesicle can be measured by measuring the signal of the labeling molecule. The amount of the pan-extracellular vesicle membrane protein can be regarded as the amount of the lectin-specific extracellular vesicle. Furthermore, the amount of exosomes may be measured by measuring the amount of proteins such as CD9, CD63, and CD81, which are considered to be pan-exosome membrane proteins.

[0041] After reacting the antibody 41 with the solid phase carrier 1, the solid phase carrier 1 may be washed with a washing solution as appropriate before detecting the solid phase carrier particles 40 or the labeling molecule. By washing the solid phase carrier 1, the antibody 41 that is not bound to the extracellular vesicles E1 can be removed. The washing solution is not particularly limited, and a washing solution used for washing in ELISA or the like can be used. Examples of the washing solution include a buffer solution or a buffer solution to which a surfactant such as Tween 20 has been added. Examples of the washing solution include, but are not limited to, PBS, PBS-T, Tris buffer solution, HEPES buffer solution, pure water, and the like.

[0042] In the step (a), when a labeled lectin that is not fixed to the solid phase carrier 1 is used, the extracellular vesicles bound to the lectin can be measured by measuring the signal of the labeling molecule used for the labeling. For example, when a fluorescent molecule is used as the labeling molecule, the extracellular vesicles bound to the lectin can be measured using flow cytometry or the like. In addition, in the step (a), when the extracellular vesicles are captured on the solid phase carrier using an antibody that specifically binds to the pan-extracellular vesicle membrane protein fixed to the solid phase carrier, and the lectin fixed to the solid phase carrier particles is brought into contact with the extracellular vesicles, the extracellular vesicles bound to the lectin can be measured by detecting the signal of the solid phase carrier particles using an extracellular vesicle measuring instrument or the like.

[0043] Specific examples of the method for carrying out steps (a) and (b) are given below, but are not limited thereto. (1) A method in which a solid phase carrier to which a lectin has been immobilized and solid phase carrier particles to which an antibody that specifically binds to a pan-extracellular vesicle membrane protein has been immobilized are used, and the amount of extracellular vesicles bound to the lectin is measured using an extracellular vesicle measuring device. (2) A method for measuring the amount of extracellular vesicles bound to lectin by immunoassays such as sandwich ELISA using a solid phase carrier to which lectin has been immobilized and an antibody that specifically binds to a pan-extracellular vesicle membrane protein labeled with a labeling molecule. (3) A method in which a solid phase carrier having an antibody that specifically binds to a pan-extracellular vesicle membrane protein immobilized thereon and solid phase carrier particles having a lectin immobilized thereon are used to measure the amount of extracellular vesicles bound to the lectin using an extracellular vesicle measuring device. (4) A method of measuring the amount of extracellular vesicles bound to lectins by immunoassays such as sandwich ELISA using a solid phase carrier onto which an antibody that specifically binds to a pan-extracellular vesicle membrane protein is immobilized and a lectin labeled with a labeling molecule. (5) A method in which a lectin labeled with a labeling molecule is used to measure the amount of extracellular vesicles bound to the lectin by flow cytometry. (6) A method in which extracellular vesicles bound to lectin are collected using lectin-immobilized magnetic beads, and the amount of extracellular vesicles bound to lectin is measured by flow cytometry using an antibody that specifically binds to a pan-extracellular vesicle membrane protein labeled with a labeling molecule. (7) A method in which extracellular vesicles are collected using magnetic beads immobilized with an antibody that specifically binds to a pan-extracellular vesicle membrane protein, and the amount of extracellular vesicles bound to a lectin labeled with a labeling molecule is measured by flow cytometry.

[0044] A more specific method for carrying out the steps (a) and (b) is, for example, the following method. Exosomes bound to lectin are collected using a solid phase carrier to which lectin has been immobilized, and the amount of the pan-exosome protein in the exosomes collected using the lectin is measured by an immunological measurement method such as ELISA, targeting the pan-exosome protein. Alternatively, pan-exosome proteins on exosomes captured on a solid phase carrier to which lectin has been immobilized are labeled with fluorescently labeled antibodies, and the amount thereof is measured using a flow cytometer.

[0045] [Process (c)] In step (c), the presence of pancreatic cancer in the subject is assessed based on the amount of extracellular vesicles measured in step (b).

[0046] The amount of extracellular vesicles (lectin-specific extracellular vesicles) measured in step (b) differs between cases where the subject from which the body fluid sample is derived has pancreatic cancer and cases where the subject does not have pancreatic cancer. Therefore, the presence of pancreatic cancer in the subject can be evaluated based on the amount of extracellular vesicles measured in step (b). More specifically, when the amount of extracellular vesicles measured in step (b) is greater or less than the amount of lectin-specific extracellular vesicles measured in a non-pancreatic cancer body fluid sample, it can be determined that the subject has pancreatic cancer. A "non-pancreatic cancer body fluid sample" refers to a body fluid sample derived from an individual who is known not to have pancreatic cancer or who is extremely unlikely to have pancreatic cancer. For example, a body fluid sample derived from an individual who has not been diagnosed with pancreatic cancer by various imaging diagnoses such as abdominal ultrasound, CT, MRI, magnetic resonance cholangiopancreatography (MRCP), endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography (ERCP), and positron emission tomography (PET) can be used as a "non-pancreatic cancer body fluid sample". A non-pancreatic cancer body fluid sample may be a body fluid sample from a so-called healthy person. It may also be a body fluid sample from a patient with a cancer other than pancreatic cancer.

[0047] The non-pancreatic cancer body fluid sample uses the same type of body fluid sample as the body fluid sample of the subject to be evaluated. For example, when the body fluid sample to be evaluated is serum, the non-pancreatic cancer body fluid sample also uses serum. The measurement of the extracellular vesicles that bind to lectin in the non-pancreatic cancer body fluid sample can be performed by the same method as the above steps (a) and (b). It is preferable to measure the extracellular vesicles that bind to lectin in the non-pancreatic cancer body fluid sample by the same method as the body fluid sample of the subject, except that the non-pancreatic cancer body fluid sample is used as the body fluid sample.

[0048] In step (c), the amount of lectin-specific extracellular vesicles in the non-pancreatic cancer body fluid sample used for comparison may be a measured value in a body fluid sample of one individual, or may be the average or median value of the measured values ​​in body fluid samples of multiple individuals. Alternatively, the amount of lectin-specific extracellular vesicles in the non-pancreatic cancer body fluid sample may be calculated by performing statistical processing such as excluding outliers on the measured values ​​of lectin-specific extracellular vesicles in multiple individuals. In addition, the amount of lectin-specific extracellular vesicles in the non-pancreatic cancer body fluid sample may be a cutoff value determined based on the amount of lectin-specific extracellular vesicles in the non-pancreatic cancer body fluid sample and the pancreatic cancer body fluid sample measured in advance. The cutoff value can be set, for example, based on an ROC curve. The ROC curve can be created by calculating the sensitivity and specificity at each cutoff value from the amount of lectin-specific extracellular vesicles in the non-pancreatic cancer body fluid sample and the pancreatic cancer body fluid sample measured in advance, and plotting them on a coordinate system with the horizontal axis representing the false positive rate (1-specificity) and the vertical axis representing the sensitivity. The cutoff value is preferably set so as to have high sensitivity and a low false positive rate.

[0049] The measurement of lectin-specific extracellular vesicles in a non-pancreatic cancer body fluid sample may be performed simultaneously with the measurement of a body fluid sample of a subject, or may be performed at a different time. For example, the amount of lectin-specific extracellular vesicles in a non-pancreatic cancer body fluid sample may be measured in advance before the measurement of a body fluid sample of a subject. In addition, when the amount of lectin-specific extracellular vesicles is measured in a plurality of non-pancreatic cancer body fluid samples, the measurement in the plurality of non-pancreatic cancer body fluid samples may be performed simultaneously or at a different time. For example, the amount of lectin-specific extracellular vesicles in a plurality of non-pancreatic cancer body fluid samples may be measured during an arbitrary period, the measured values ​​may be accumulated, and the value calculated by statistically processing the accumulated measured values ​​may be used as the amount of lectin-specific extracellular vesicles in the non-pancreatic cancer body fluid sample.

[0050] When the lectin used in step (a) is selected from the group consisting of DSA, STL, LEL, ACA, UDA, ABA, MAH, and TJA-1, if the amount of extracellular vesicles measured in step (b) is greater than the amount measured in a non-pancreatic cancer body fluid sample, it can be evaluated that pancreatic cancer is present in the subject. For example, if the amount of extracellular vesicles measured in step (b) is 1.2 times or more, preferably 1.5 times or more, more preferably 2 times or more, the amount measured in a non-pancreatic cancer body fluid sample, it can be evaluated that pancreatic cancer is present in the subject. On the other hand, if the amount of extracellular vesicles measured in step (b) is the same as or lower than the amount measured in a non-pancreatic cancer body fluid sample, it can be evaluated that the possibility of pancreatic cancer being present in the subject is low. "Similar to the amount measured in a non-pancreatic cancer body fluid sample" means, for example, less than 1.2 times, preferably 1.1 times or less, more preferably 1 times or less, the amount measured in a non-pancreatic cancer body fluid sample.

[0051] When two or more lectins are used in step (a), measurements of extracellular vesicles bound to each type of lectin are obtained in step (b). In this case, in step (c), these measurements may be combined to evaluate the presence of pancreatic cancer in the subject. For example, when all of the measurements in two or more lectins are greater than the measurements in a non-pancreatic cancer body fluid sample, the subject may be evaluated as having pancreatic cancer. In this case, the more lectins used in step (a), the more accurate the evaluation of the presence of pancreatic cancer in the subject. Alternatively, when at least one of the measurements in two or more lectins is greater than the measurements in a non-pancreatic cancer body fluid sample, the subject may be evaluated as having pancreatic cancer. In this case, subjects with a high possibility of having pancreatic cancer can be widely captured. Alternatively, when a certain proportion (e.g., a majority) of the measurements in two or more lectins is greater than the measurements in a non-pancreatic cancer body fluid sample, the subject may be evaluated as having pancreatic cancer.

[0052] In step (c), the stage of pancreatic cancer whose presence in the subject is evaluated is not particularly limited. The method for detecting pancreatic cancer of this embodiment can detect any of pancreatic cancer stages I to IV. The method for detecting pancreatic cancer of this embodiment can detect early stage pancreatic cancer of stage I, so that it can be suitably used for screening early stage pancreatic cancer.

[0053] In addition, the pancreatic cancer whose presence in the subject is evaluated in step (c) may be pancreatic cancer that has recurred after surgery. When pancreatic cancer is surgically removed, the amount of lectin-specific extracellular vesicles decreases to the same level as in non-pancreatic cancer body fluid samples. However, when pancreatic cancer recurs, the amount of lectin-specific extracellular vesicles is expected to increase again. Therefore, the pancreatic cancer detection method of this embodiment can be suitably used as a method for monitoring the therapeutic effect of pancreatic cancer.

[0054] [Optional process] The detection method of this embodiment may include optional steps in addition to the above steps (a) to (c), such as a step of performing a blocking treatment of the solid phase carrier 1 before step (a) (blocking step), a step of treating pancreatic cancer after step (c) (treatment step), etc.

[0055] <Blocking process> Before step (a), a blocking treatment may be performed on the solid phase carrier 1 to which the lectin 10 is immobilized. By performing the blocking treatment, it is possible to suppress non-specific binding of extracellular vesicles that do not bind to the lectin 10 to the solid phase carrier 1. The blocking treatment can be carried out using a known blocking solution. Any blocking solution commonly used in ELISA and the like can be used without any particular limitation. Examples of blocking solutions include a buffer solution containing about 1 to 5% skim milk or bovine serum albumin (BSA). The buffer solution for the blocking solution is not particularly limited, and examples thereof include PBS, PBS-T, Tris buffer, HEPES buffer, and the like.

[0056] <Treatment process> If the subject is assessed to have pancreatic cancer in step (c), a step of treating the pancreatic cancer may be carried out. Thus, the present invention provides (a) contacting extracellular vesicles in a body fluid sample derived from a subject with one or more lectins; After the step (a), a step (b) of measuring the amount of the extracellular vesicles bound to the one or more lectins; (c) evaluating the presence of pancreatic cancer in the subject based on the amount of extracellular vesicles measured in the step (b); If the subject is evaluated to have pancreatic cancer in step (c), a step (d) of treating the pancreatic cancer. Also provided is a method for treating pancreatic cancer, comprising:

[0057] The step (c) can also be said to be a step of diagnosing whether the subject is suffering from pancreatic cancer based on the amount of extracellular vesicles measured in step (b).

[0058] The method of treating pancreatic cancer is not particularly limited, and methods commonly used in the treatment of pancreatic cancer can be used. For example, surgical resection of pancreatic cancer, radiation therapy, administration of anticancer drugs (gemcitabine, TS-1, erlotinib, etc.), etc. can be mentioned.

[0059] In addition, after step (c), and before treatment of pancreatic cancer, a definitive diagnosis of pancreatic cancer may be made by various imaging diagnostics such as abdominal ultrasound, CT, MRI, magnetic resonance cholangiopancreatography (MRCP), endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography (ERCP), and positron emission tomography (PET), as well as cytology or histology. Subjects who have been definitively diagnosed with pancreatic cancer by these methods may be treated for pancreatic cancer.

[0060] According to the method for detecting pancreatic cancer of the present embodiment, pancreatic cancer can be detected in vitro using a body fluid sample of a subject, so that pancreatic cancer can be easily detected by a non-invasive method. In addition, according to the method for detecting pancreatic cancer of the present embodiment, pancreatic cancer can be detected early. In addition, the effect of treatment for pancreatic cancer can be monitored.

[0061] (Pancreatic cancer detection kit) In one embodiment, the present invention provides a pancreatic cancer detection kit comprising a solid phase carrier to which one or more lectins are immobilized and an antibody or an antigen-binding fragment thereof that specifically binds to a pan-extracellular vesicle membrane protein.

[0062] [Solid support with one or more lectins immobilized] The solid phase carrier having one or more lectins immobilized thereon may be the same as that described in [Step (a)] of the above (Method for detecting pancreatic cancer) (e.g., solid phase carrier 1 shown in FIG. 1A). When two or more types of lectins are used, it is preferable that one type of lectin is immobilized on one solid phase carrier. Alternatively, one solid phase carrier may be partitioned into the number of lectin types, and one type of lectin may be immobilized on one partition. The lectin immobilized on the solid phase carrier preferably includes at least one type selected from the group consisting of DSA, STL, LEL, ACA, UDA, ABA, MAH, and TJA-1, and more preferably includes at least one type selected from the group consisting of ACA and ABA.

[0063] [Antibody or antigen-binding fragment thereof that specifically binds to a pan-extracellular vesicle membrane protein] The antibody or its antigen-binding fragment that specifically binds to the pan-extracellular vesicle membrane protein can be the same as that described in [step (b)] of the above (method for detecting pancreatic cancer). The pan-extracellular vesicle membrane protein may be a pan-exosome membrane protein. Examples of the pan-exosome membrane protein include CD9, CD63, and CD81.

[0064] The antibody or antigen-binding fragment thereof that specifically binds to the pan-extracellular vesicle membrane protein may be immobilized on a solid-phase carrier particle or may be labeled with a labeling molecule. The solid-phase carrier particle and the labeling molecule may be the same as those listed above.

[0065] <Pancreatic cancer detection kit used in extracellular vesicle counter> The pancreatic cancer detection kit of this embodiment may be used in an extracellular vesicle measuring instrument. The extracellular vesicle measuring instrument may be a commercially available one, such as ExoCounter (registered trademark) (JVC Kenwood). When used in an extracellular vesicle measuring instrument, the solid-phase carrier to which one or more lectins are immobilized may be one provided in an extracellular vesicle capture unit used in the extracellular vesicle measuring instrument. In addition, the antibody or antigen-binding fragment thereof that specifically binds to the pan-extracellular vesicle membrane protein may be one immobilized on a solid-phase carrier particle.

[0066] <Extracellular vesicle capture unit> The extracellular vesicle capturing unit can be one that corresponds to the extracellular vesicle counter to be used. The solid phase carrier provided in the extracellular vesicle capturing unit can be, for example, one having a form such as the solid phase carrier 1 in FIG. 1A. Hereinafter, with reference to FIGS. 2A to 2C and 3A to 3B, an example of an extracellular vesicle capturing unit provided with the solid phase carrier 1 will be described.

[0067] Fig. 2A is a schematic top view of the extracellular vesicle capturing unit 50. Fig. 2B is a schematic cross-sectional view taken along the AA line in Fig. 2A. Fig. 2C is a schematic cross-sectional view for explaining that the cartridge 52 is detachable from the substrate 51. Fig. 3A is a partially enlarged perspective view taken along the BB line in Fig. 2A.

[0068] As shown in FIG. 2A, the extracellular vesicle capturing unit 50 is configured to include a substrate 51 and a cartridge 52.

[0069] The substrate 51 has a disk shape similar to that of an optical disc such as a Blu-ray disc (BD), a DVD, a compact disc (CD), etc. The substrate 51 is formed of a resin material such as polycarbonate resin or cycloolefin polymer that is generally used for optical discs.

[0070] As shown in Fig. 3A, a track area 55 is formed on the surface of a substrate 51, in which protrusions 3 and recesses 2 are alternately arranged in the radial direction. The protrusions 3 and recesses 2 are formed in a spiral shape from the inner periphery to the outer periphery. The protrusions 3 correspond to the lands of an optical disc. The recesses 2 correspond to the grooves of an optical disc.

[0071] The substrate 51 corresponds to the solid phase carrier 1 in Fig. 1A, and the convex portions 3 and concave portions 2 formed on the substrate 51 correspond to the convex portions 3 and concave portions 2 in Fig. 1A, respectively. In the track region 55 in the substrate 51 in which the concave portions 2 and the convex portions 3 are formed, a lectin 10 is immobilized at least in the concave portion 2.

[0072] 2A, the cartridge 52 has a ring shape. The cartridge 52 has a plurality of cylindrical through holes 56 formed in the circumferential direction.

[0073] As shown in Figures 2B and 3A, the extracellular vesicle capturing unit 50 has a plurality of wells 57 formed by the through-holes 56 of the cartridge 52 and the track areas 55 of the substrate 51. That is, the inner circumferential surface of the through-holes 56 constitutes the inner circumferential surface of the wells 57, and the track areas 55 of the substrate 51 constitutes the bottom surface of the wells 57. The wells 57 are containers for storing sample liquids and the like. In addition, if a packing made of an elastically deformable material such as silicone rubber is inserted between the through-holes 56 and the substrate 51, the possibility of leakage of the solution can be reduced, which is advantageous.

[0074] 2C, the cartridge 52 is detachable from the substrate 51. Detection of extracellular vesicles after capture of the extracellular vesicles is performed by removing the cartridge 52 from the substrate 51 and using the substrate 51 alone.

[0075] In the extracellular vesicle capturing unit 50, the contact between the extracellular vesicles in the body fluid sample and the lectin 10 immobilized on the track region 55 in the step (a) can be performed by introducing the body fluid sample into the well 57. When an antibody 41 that specifically binds to a pan-extracellular vesicle membrane protein is used in the step (b), the reaction between the antibody 41 and the extracellular vesicles E1 bound to the lectin 10 can be performed by introducing a solution containing the antibody 41 into the well 57. When performing a washing process, a blocking process, or the like, the washing solution, the blocking solution, or the like can be introduced into the well 57. Before introducing a solution for each process into the well 57, it is preferable to remove the solution used in the previous process from the well 57.

[0076] <Solid phase carrier particles> The solid-phase carrier particles can be selected according to the extracellular vesicle counter used. Examples of the solid-phase carrier particles include resin particles such as polystyrene and glycidyl methacrylate, as well as magnetic beads. The solid-phase carrier particles have an antibody that specifically binds to the pan-extracellular vesicle membrane protein immobilized thereon. Examples of the solid-phase carrier particles include the solid-phase carrier particles 40 to which the antibody 41 in FIG. 1C is immobilized.

[0077] Next, the relationship between the dimensions of the recesses 2 and protrusions 3 formed on the substrate 51 of the extracellular vesicle capturing unit 50, the dimensions of the solid-phase carrier particles, and the average particle size of the extracellular vesicles will be described.

[0078] 3B is an enlarged cross-sectional view for explaining the dimensional shapes of the recessed portion 2 and the protruding portion 3 formed in the track region 55 of the substrate 51. The depth of the recessed portion 2 (the height of the protruding portion 3) is H, the width of the recessed portion 2 is Wa, and the width of the protruding portion 3 is Wb. The widths Wa and Wb are the widths at the position H / 2 indicated by the dotted lines.

[0079] The width Wb of the protrusions 3 is preferably smaller than the average particle size Ra of the extracellular vesicles, as shown in the following formula (1). By satisfying the following formula (1), the extracellular vesicles are less likely to be located on the protrusions 3. Wb < Ra ···(1)

[0080] The width Wa of the recess 2 is preferably larger than the average particle diameter Ra of the extracellular vesicles and smaller than four times the average particle diameter Ra, as shown in the following formula (2). By satisfying the following formula (2), it becomes easier to capture the extracellular vesicles in the recess 2. Ra < Wa < 4×Ra ···(2)

[0081] The extracellular vesicles captured in the recess 2 generally deform from a spherical shape in a direction to increase the contact area. Assuming that a spherical extracellular vesicle deforms into an ellipsoid while maintaining its volume, when the diameter of the sphere changes by 50%, the diameter of the contact part with the recess 2, which is the major axis of the prolate ellipsoid, becomes about 40% larger. Furthermore, in actuality, since it deforms in a direction to increase the area of the contact part more than the prolate ellipsoid shape, the diameter of the contact part may increase by 50% or more, and in some cases, 100% or more, of the diameter in the original spherical state. Therefore, it is preferable to satisfy Wa < 4×Ra in the above formula (2).

[0082] Also, the width Wa of the recess 2, the width Wb of the protrusion 3, and the particle diameter Rc of the solid-phase carrier particles preferably satisfy the following formula (3). Wb < Rc < Wa < 2×Rc ···(3)

[0083] By satisfying Wb < Rc in the above formula (3), it becomes difficult for the solid-phase carrier particles to be located on the protrusion 3. By satisfying Rc < Wa in the above formula (3), it becomes easier for the solid-phase carrier particles to enter the recess 2. By satisfying Wa < 2×Rc in the formula (3), it becomes difficult for two or more solid-phase carrier particles to enter simultaneously in the width direction of the recess 2, and the quantitative relationship between the extracellular vesicles and the solid-phase carrier particles can be made closer to 1:1.

[0084] As shown in the following formula (4), the particle diameter Rc of the solid-phase carrier particles is preferably larger than the average particle diameter Ra of the extracellular vesicles. Ra < Rc ···(4)

[0085] By satisfying the above formula (4), multiple solid carriers are less likely to bind to the extracellular vesicles fixed to the recesses 2, and the quantitative relationship between the extracellular vesicles and the solid carrier particles can be brought closer to 1:1. By satisfying formula (4), the probability that the extracellular vesicles and the solid carrier particles will reactively encounter each other increases, and as a result, the reaction yield can be improved.

[0086] As shown in the following formula (5), the depth H of the recess 2 is preferably greater than 1 / 8 times the sum of the average particle size Ra of the extracellular vesicles and the particle size Rc of the solid phase carrier particles. (Ra+Rc) / 8 <H ···(5)

[0087] By satisfying the above formula (5), extracellular vesicles are easily captured in the recesses 2. In addition, nonspecific adsorption of the solid-phase carrier particles to the protrusions 3 is less likely to occur, and the solid-phase carrier particles are more likely to bind to the extracellular vesicles captured in the recesses 2.

[0088] It is more preferable that the depth H of the recess 2 satisfies the formula (6). (Ra+Rc) / 6 <H ···(6)

[0089] The recesses 2, the protrusions 3, and the solid-phase carrier particles preferably satisfy all of the above formulas (1) to (5) (or formula (6)), but may only partially satisfy them.

[0090] [Optional configuration] The pancreatic cancer detection kit of this embodiment may include any other components in addition to the above components, such as a reagent for treating a body fluid sample (e.g., a diluent, etc.), various reagents such as a washing solution, a blocking solution, and a buffer solution, and instructions for use.

[0091] When the antibody or antigen-binding fragment thereof that specifically binds to the pan-extracellular vesicle membrane protein is labeled with a labeling molecule, the kit may contain a detection reagent for detecting the labeling molecule. A known detection reagent may be used depending on the type of label. Furthermore, the pancreatic cancer detection kit of this embodiment may contain a standard reagent. The standard reagent is a reagent for creating a calibration curve of lectin-specific extracellular vesicles. For example, the standard reagent may contain a glycan to which a lectin fixed to a solid phase carrier binds.

[0092] The pancreatic cancer detection kit of this embodiment can be used in the pancreatic cancer detection method of the above embodiment.

[0093] (Other Aspects) The present invention may also include the following aspects. (1) A method for diagnosing pancreatic cancer, comprising: a step (a) of contacting extracellular vesicles in a body fluid sample derived from a subject with one or more lectins in vitro; a step (b) of measuring the amount of the extracellular vesicles bound to the one or more lectins after the step (a); and a step (c) of evaluating the presence of pancreatic cancer in the subject based on the amount of the extracellular vesicles measured in the step (b). (2) A method for identifying a body fluid sample derived from a subject having pancreatic cancer, comprising: a step (a) of contacting extracellular vesicles in a body fluid sample derived from a subject with one or more lectins in vitro; a step (b) of measuring the amount of the extracellular vesicles bound to the one or more lectins after the step (a); and a step (c) of evaluating the presence of pancreatic cancer in the subject based on the amount of the extracellular vesicles measured in the step (b). (3) A method for collecting data for diagnosing pancreatic cancer, comprising: (a) contacting extracellular vesicles in a body fluid sample derived from a subject with one or more lectins in vitro; (b) measuring the amount of the extracellular vesicles bound to the one or more lectins after the step (a); and (c) evaluating the presence of pancreatic cancer in the subject based on the amount of the extracellular vesicles measured in the step (b). (4) A method for monitoring the effectiveness of a pancreatic cancer treatment, comprising: a step (a) of contacting extracellular vesicles in a body fluid sample derived from a subject undergoing a pancreatic cancer treatment with one or more lectins in vitro; a step (b) of measuring the amount of the extracellular vesicles bound to the one or more lectins after the step (a); and a step (c) of evaluating the presence of pancreatic cancer in the subject based on the amount of the extracellular vesicles measured in the step (b). (5) A method for collecting data for evaluating the effectiveness of a pancreatic cancer treatment, comprising: (a) contacting extracellular vesicles in a body fluid sample derived from a subject undergoing treatment for pancreatic cancer with one or more lectins in vitro; (b) measuring the amount of the extracellular vesicles bound to the one or more lectins after the step (a); and (c) evaluating the presence of pancreatic cancer in the subject based on the amount of the extracellular vesicles measured in the step (b). (6) Use of a lectin and an antibody that specifically binds to a pan-extracellular vesicle membrane protein for the manufacture of a diagnostic kit for pancreatic cancer. (7) Use of a lectin and an antibody that specifically binds to a pan-extracellular vesicle membrane protein to diagnose pancreatic cancer. (8) An antibody that specifically binds to a lectin and a pan-extracellular vesicle membrane protein for use in diagnosing pancreatic cancer. In the above (1) to (8), the lectin preferably includes at least one selected from the group consisting of DSA, STL, LEL, ACA, UDA, ABA, MAH, and TJA-1, and more preferably includes at least one selected from the group consisting of ABA and ACA. In the above (1) to (5), steps (a) to (c) can be carried out in the same manner as described above. In the above (7) and (8), examples of the pan-extracellular vesicle membrane protein include CD9, CD63, and CD81. EXAMPLES

[0094] The present invention will be described below with reference to examples, but the present invention is not limited to the following examples.

[0095] (Selection of candidate lectins) Exosomes were isolated from the serum of pancreatic cancer patients and healthy subjects using the Magcapture Exosome Isolation Kit (Fujifilm, Tokyo, Japan). Exosomes were resuspended in buffer and labeled with Cy3-succimidyl ester (SE; Amersham Biosciences, Tokyo, Japan). The samples were reacted with a lectin array (LecChip®, GP Biosciences, Yokohama, Japan) on which 45 types of lectins were immobilized, and exosomes that could bind to each lectin were immobilized. The immobilized exosomes were analyzed using an evanescent fluorescence scanner.

[0096] As a result, it was found that the amount of exosomes that specifically bind to certain lectins increases in the serum of pancreatic cancer patients. The lectins that increase the amount of exosomes that bind to them in the serum of pancreatic cancer patients are shown in Table 1. The p values ​​in Table 1 were calculated using the Mann-Whitney U-test. The figures in parentheses indicate the 95% confidence interval (CI).

[0097] [Table 1]

[0098] The above results suggest that detecting exosomes that bind to specific lectins may enable the detection, diagnosis, and monitoring of the progression or treatment effects of pancreatic cancer.

[0099] The results shown in Table 1 were evaluated comprehensively, and ABA and ACA were selected as candidate lectins for use in the following tests.

[0100] (Method for measuring exosomes that bind to lectins) In the following tests, exosomes with glycans that bind to ABA or ACA (hereinafter referred to as "ABA / ACA-specific exosomes") were measured by sandwich immunoassay. The procedure of the sandwich immunoassay is as follows. 1) Prepare magnetic beads whose surfaces are modified with carboxyl groups, and covalently bind anti-CD9 antibodies to them. Specifically, follow the procedure below. PBS (pH 7.4) containing 400 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) and N-hydroxysuccinimide was added to FG beads (COOH beads; Tamagawa Seiki) and reacted at room temperature for 4 hours. Wash the beads with 50 mM acetate buffer (pH 5.2). An acetate buffer (pH 5.2) containing 1.0 g / L of anti-CD9 antibody or anti-CD63 antibody was added to the beads, and the reaction was carried out overnight at 4°C to immobilize the antibody. PBS (pH 7.4) containing 0.1 M ethanolamine was added to the beads and reacted at 4°C for 5 hours to mask unreacted carboxyl groups. The cells were washed with HEPES buffer (10 mM HEPES, pH 7.9) containing 150 mM KCl, 5 mM EDTA and 0.1% Tween 20, and stored at 4°C. 2) ABA or ACA is bound to the disk (extracellular vesicle capture unit) of ExoCounter (registered trademark) (JVC Kenwood, Yokohama, Japan). Specifically, a carbonate buffer (pH 9.6) containing 5 mg / mL of lectin is added to the disk, and the disk is allowed to stand at 37° C. for 30 minutes. 3) Wash the disk with 0.05% PBS-T (pH 7.4). 4) The culture supernatant of the cancer cell line or the serum of the subject is appropriately diluted with a buffer solution (PBS or PBS-T) and reacted with ABA or ACA on the disk (37°C, 2 hours, shaking at 1000-1500 rpm). 5) Wash the disk with 0.05% PBS-T (pH 7.4). 6) Magnetic beads bound to anti-CD9 antibodies are suspended in 0.05% PBS-T (pH 7.4) at 20 μg / mL and reacted with exosomes bound to ABA or AC on the disk (37°C, 1.5 hours). This reaction may be performed by using a magnet to rapidly collect magnetism on the disk surface and cause the reaction. 7) Wash the disk with PBS-T. The final wash is with pure water. 8) Allow the disc to dry. 9) Place the disk in the ExoCounter and measure exosomes.

[0101] In the above procedure, exosomes are captured on the detection disk using lectin (ABA or ACA), and ABA / ACA-specific exosomes are revealed by using nanobeads immobilized with an antibody against CD9, which is believed to be ubiquitously expressed in exosomes. When serum was used in 4) above, it was diluted 4-fold with PBS-T.

[0102] (Evaluation of candidate lectins using cancer cell lines) <Measurement of ABA / ACA-specific xosome number> We investigated whether there were differences in the amount of ABA / ACA-specific exosomes between cancer types using culture supernatants from various cancer cell lines (pancreatic cancer cell lines: BxPC33, Capan-1; breast cancer cell line: MCF7; colon cancer cell line: HCT116; lung cancer cell line: A549). ABA / ACA-specific exosomes were quantified using the method described above in <Method for measuring exosomes that bind to lectins>.

[0103] The results are shown in Figure 4. Exosomes specific to both ABA and ACA lectins were detected in all cancer cell lines. Among them, exosomes binding to ABA and ACA were detected at high levels in the pancreatic cancer cell lines BxPC3 and Capan-1.

[0104] <Ratio of ABA / ACA-specific exosomes to total exosomes> The amount of exosome secretion varies depending on the type of cell line. Therefore, the ratio of ABA / ACA-specific exosomes to the total amount of exosome secretion is important. Therefore, using the same sample as above, exosomes were captured on a disk immobilized with CD63 antibody and exosomes were detected using beads immobilized with CD9 antibody. CD63 is a membrane protein that is thought to be ubiquitously expressed on exosomes, similar to CD9. Therefore, this measurement result can be said to represent the total number of exosomes in the sample. Using this measurement, the ratio of ABA- or ACA-specific exosomes to the total exosomes was evaluated by normalizing the measured numbers shown in Figure 1 by the measured numbers of CD63 and CD9.

[0105] The results are shown in Figure 5. The ratio of ABA / ACA-specific exosomes to total exosomes was much higher in pancreatic cancer cell lines (BxPC3, Capan-1) than in other cancer cell lines.

[0106] Example 1 Comparison of ABA / ACA-specific exosome numbers between healthy subjects and pancreatic cancer patients Using serum from healthy subjects and pre- and post-surgery serum from pancreatic cancer patients, we investigated whether there was a difference in the amount of ABA / ACA-specific exosomes between the sera. The amount of ABA / ACA-specific exosomes was quantified by the method described in the above <Method for measuring exosomes that bind to lectins>. The serum was diluted 4-fold with PBS-T before use.

[0107] The results are shown in Figure 6. Both ABA-specific exosomes and ACA-specific exosomes were statistically significantly higher in the preoperative serum of pancreatic cancer patients (PC / Preoperative) than in the serum of healthy subjects (NC). On the other hand, in the postoperative serum of pancreatic cancer patients (PC / Postoperative), both exosomes were decreased compared to preoperative serum, and the difference was statistically significant. These results demonstrated that ABA-specific exosomes and ACA-specific exosomes can be used to detect pancreatic cancer and monitor the recurrence of pancreatic cancer after surgery.

[0108] Example 2 Comparison of ABA / ACA-specific exosome numbers between pancreatic cancer and other cancer types We investigated whether there were differences in the amount of ABA / ACA-specific exosomes between cancer types using serum from healthy subjects, pancreatic cancer patients, esophageal cancer patients, and colorectal cancer patients. ABA / ACA-specific exosomes were quantified using the method described above in <Method for measuring exosomes that bind to lectins>.

[0109] The results are shown in Figure 7. In pancreatic cancer patient sera (PC), both ABA-specific exosomes and ACA-specific exosomes were found to be higher than in esophageal cancer patient sera (Esophageal Cancer) and colorectal cancer patient sera (Colorectal Cancer). These results indicate that ABA-specific exosomes and ACA-specific exosomes are effective for the specific detection of pancreatic cancer.

[0110] Example 3 Comparison of ABA / ACA-specific exosome numbers between pancreatic cancer patients at different stages Using serum from healthy subjects and serum from patients with stage I, II, and III pancreatic cancer, we investigated whether there was a difference in the amount of ABA / ACA-specific exosomes among the sera. The amount of ABA / ACA-specific exosomes was quantified by the method described in the above <Method for measuring exosomes that bind to lectins>.

[0111] The results are shown in Figure 8. In the serum of stage I pancreatic cancer patients, both ABA-specific exosomes and ACA-specific exosomes were statistically significantly higher than in the serum of healthy subjects (NC). These results indicate that ABA / ACA-specific exosomes are effective for the early detection of pancreatic cancer. [Industrial Applicability]

[0112] According to the present invention, liquid biopsy enables early detection of pancreatic cancer and monitoring of the effectiveness of treatment. Collect data to , pancreatic cancer Data collectionMethods and kits for detecting pancreatic cancer are provided. [Explanation of symbols]

[0113] 1...solid phase support, 2...concave portion, 3...convex portion, 10...lectin, 21, 22, 23...glycan, 31...pan-extracellular vesicle membrane protein, 40...solid phase support particle, 41...antibody that specifically binds to the pan-extracellular vesicle membrane protein, 50...extracellular vesicle capture unit, 51...substrate, 52...cartridge, 55...track area, 56...through-hole, 57...well.

Claims

1. (a) contacting extracellular vesicles in a body fluid sample derived from a subject with one or more lectins; After the step (a), a step (b) is performed to count the number of extracellular vesicles bound to the one or more lectins by contacting the extracellular vesicles bound to the one or more lectins with solid-phase carrier particles to which an antibody or an antigen-binding fragment thereof that specifically binds to a pan-extracellular vesicle membrane protein is immobilized and detecting a signal from the solid-phase carrier particles bound to the extracellular vesicles bound to the lectin; Including, The one or more lectins include DSA, A data collection method for pancreatic cancer, comprising collecting the number of extracellular vesicles bound to the lectin counted in step (b) as data for evaluating pancreatic cancer.

2. The one or more lectins further include at least one lectin other than the DSA. The method for collecting data on pancreatic cancer according to claim 1 .

3. The method for collecting data on pancreatic cancer according to claim 2, wherein the at least one lectin other than DSA includes at least one selected from the group consisting of STL, LEL, ACA, UDA, ABA, MAH, and TJA-1.

4. The method for collecting data on pancreatic cancer according to any one of claims 1 to 3, wherein the pan-extracellular vesicle membrane protein is selected from the group consisting of CD9, CD63, and CD81.

5. A solid phase carrier having one or more lectins immobilized thereon; A solid-phase carrier particle having an antibody or an antigen-binding fragment thereof that specifically binds to a pan-extracellular vesicle membrane protein immobilized thereon; Including, The one or more lectins include DSA. Pancreatic cancer detection kit.

6. The one or more lectins include at least one lectin other than the DSA. The pancreatic cancer detection kit according to claim 5 .

7. The pancreatic cancer detection kit according to claim 6, wherein the at least one lectin other than DSA includes at least one selected from the group consisting of STL, LEL, ACA, UDA, ABA, MAH, and TJA-1.

8. The pancreatic cancer detection kit according to any one of claims 5 to 7, wherein the pan-extracellular vesicle membrane protein is selected from the group consisting of CD9, CD63, and CD81.

9. The pancreatic cancer detection kit further includes an extracellular vesicle capture unit used in an extracellular vesicle counter used to count the number of extracellular vesicles bound to the DSA by detecting a signal from a solid-phase carrier particle bound to the DSA-bound extracellular vesicles; The solid phase carrier is provided in the extracellular vesicle capture unit. The pancreatic cancer detection kit according to claim 5 .

10. The pancreatic cancer detection kit includes an extracellular vesicle capture unit used in an extracellular vesicle counter used to count the number of extracellular vesicles bound to the DSA by detecting a signal from a solid-phase carrier particle bound to the DSA, and to count the number of extracellular vesicles bound to at least one lectin other than the DSA by detecting a signal from a solid-phase carrier particle bound to the DSA, The pancreatic cancer detection kit according to any one of claims 6 to 8, wherein the solid phase carrier is provided in the extracellular vesicle capture unit.

Citation Information

Patent Citations

  • Methods and compositions for quantifying exosomes

    US20130323756A1

  • Means and methods for glycoprofiling of a protein

    WO2019185515A1